Additional Functionality Requested by Customers Enhances
Ease of Deployment, Compatibility With Industry Analysis Tools
MOUNTAIN VIEW, Calif., Aug. 24 /PRNewswire-FirstCall/ -- Pharsight
Corporation (OTC Bulletin Board: PHST), a leading provider of software and
strategic services designed to optimize clinical drug development, today
announced the release of Drug Model Explorer(TM) Web Server (DMX(TM)) 1.4.
The new release will support Oracle(R) and allow DMX to read and process
simulation data created in SAS(R) XPORT transport format. Oracle is the
preferred database system in the pharmaceutical industry and SAS XPORT is a
data exchange mechanism accepted by the Food and Drug Administration (FDA).
DMX is a web-based tool that allows clinical drug development teams to
communicate, present and exchange information on drug attributes quickly and
efficiently and compare probable outcomes based on different treatment
strategies, patient populations and competing products.
DMX will continue to support Microsoft(R) SQL Server, a leading database
product, and will continue to process simulations created in S-PLUS(R), a
leading analysis software product.
"We are committed to working closely with our customers to meet their
changing and emerging technology needs," said Shawn M. O'Connor, President and
Chief Executive Officer. "By supporting Oracle and SAS XPORT format in DMX,
the value of our software products increases through enhanced compatibility
with our customers' existing workflows and drug development technology
infrastructures. Our customers highly value products that will allow them to
focus more resources on their core business of drug development, and not, for
example, on information technology. By incorporating this upgraded
functionality that is directly in response to our customers' needs so quickly
after our commercial launch, we believe we are illustrating our commitment to
being responsive to our customers and to remaining at the forefront of
technology development."
About DMX
DMX allows clinicians, biostatisticians, marketers, and other members of
clinical development teams to quickly visualize the modeled efficacy, safety,
and other performance attributes of a new drug versus competing therapies.
Pharsight believes that DMX will help increase the usage of quantitative-based
decision-making in the drug development process. DMX can enhance the entire
development team's understanding of a drug's likely clinical potential and
limitations, and enable more efficient decision-making by providing direct
interaction with modeling results presented as a series of intuitive plots and
tables.
Key new features and functionality of DMX Web Server 1.4 include:
-- Support for Oracle, the preferred database system in the
pharmaceutical industry
-- Ability to read and process simulations created in SAS XPORT format,
a data exchange mechanism accepted by the FDA
-- Desktop publishing tools no longer require installation of source
software (S-PLUS, SAS) used to generate DMX-ready simulations,
increasing ease of deployment
-- Publishing tools support packaging of all simulation objects into a
single file
About Pharsight Corporation
Pharsight Corporation develops and markets products and services that help
pharmaceutical and biotechnology companies improve their decision-making in
drug development and commercialization. By integrating scientific, clinical
and business decision criteria into a dynamic, model-based methodology,
Pharsight helps its customers optimize the value of their drug development
programs and portfolios from discovery to post-launch marketing and any point
in between. Pharsight uses computer-based drug-disease models, dynamic
predictive market models, clinical trial simulation and advanced valuation
models to create a continuously evolving view of its customers' development
efforts and product portfolios. This enables decision makers to make explicit
value-driven trade-offs throughout the development and commercialization
process. Pharsight Corporation is headquartered in Mountain View, California.
Information about Pharsight is available on the World Wide Web at
http://www.pharsight.com.
NOTE: Pharsight, WinNonlin and WinNonMix, Pharsight Knowledgebase Server,
PKS, Drug Model Explorer, DMX, PKS Reporter and Trial Simulator are registered
trademarks or trademarks of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks
of their respective holders.
Safe Harbor
This press release includes forward-looking statements, including
statements regarding customer demand for Pharsight's software products,
services and technology, Pharsight's anticipated software product development
and performance, and the expected benefits to customers from the use of
Pharsight's products. Actual results may differ materially from Pharsight's
expectations due to a variety of factors including: general market and
business conditions; uncertainties in pharmaceutical drug development; changes
in the demand for Pharsight's products and services; changes in Pharsight
research and development focus or operating strategies; the failure to develop
new products and services or to keep pace with technological changes; delays
in the release of new products and services; and the failure of products and
services to obtain anticipated levels of customer acceptance or to meet
customers' expectations. Further information on potential factors that could
affect actual results is included in Pharsight's Quarterly Report on
Form 10-Q, as filed with the Securities and Exchange Commission on August 9,
2005. All forward-looking statements are based on information available to
Pharsight as of the date hereof, and Pharsight assumes no obligation to update
such statements, whether as a result of new developments or otherwise.
SOURCE Pharsight Corporation
 back to top
Related links:
http://www.pharsight.com
CONTACT:
Investors, Douglas Sherk, +1-415-896-6820, or
Jennifer Beugelmans, +1-415-896-6820, or Media, Steve DiMattia,
+1-917-620-0590, all of EVC Group, for Pharsight Corporation
|
